What is pemvidutide? Structure, research and status

Pemvidutide is an investigational peptide that activates both the glucagon receptor and the GLP-1 receptor, developed by Altimmune for liver diseases and alcohol use disorder.

Complete guide10 min read

Key takeaway

Pemvidutide, code name ALT-801, is a dual glucagon receptor and GLP-1 receptor agonist. In the IMPACT trial, MASH resolved without fibrosis worsening in 58% and 52% of two pemvidutide groups at 24 weeks, versus 20% on placebo. The second primary endpoint, fibrosis improvement, was not met. Nausea, diarrhea and constipation were the most frequent drug-related events.

At a glance

Article typeComplete guide
Regulatory statusIn clinical trials“Pemvidutide is not approved by the FDA for any use.” (this article)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited6 in this article · 6 across 1 article on Pemvidutide
Related productsIncretin analogs

Pemvidutide is a 29-amino-acid peptide carrying a sugar and fatty acid group that binds albumin in the blood. Its designers built it to act on the glucagon and GLP-1 receptors with near-equal potency. Its phase 2b trial in the fatty liver disease MASH was published in 2025 and 2026. A phase 3 trial began in July 2026.

Quick answer: Pemvidutide is an investigational peptide drug in a phase 3 trial for MASH. Phase 2 trials cover alcohol use disorder and alcohol-associated liver disease. Pemvidutide is not approved by the FDA for any use.

Vitrapep does not sell pemvidutide; this page is a reference summary of published research and regulatory information.

What is pemvidutide and how is it built?

Pemvidutide began at Spitfire Pharma as SP-1373, and Altimmune later developed it as ALT-801 [4]. Its designers sought evenly balanced potency at the GLP-1 and glucagon receptors [3]. They described it in 2021 as compound 17 from a series of glycolipid-modified peptides [3].

The peptide combines sequence elements of GLP-1 and glucagon in a stabilized structure [4]. FDA's substance registry gives the sequence as His-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-Ala-Ala-Lys-Glu-Phe-Ile-Gln-Trp-Leu-Leu-Gln-Thr, with an amidated end [2].

Three features stand out. Position 2 carries 2-methylalanine (Aib), an amino acid not encoded by genes [2]. A lactam bridge joins the side chains at positions 16 and 20 [1], [2]. The lysine at position 17 carries the EuPort glycolipid [4]. It joins a glucuronic acid sugar to an 18-carbon chain ending in a carboxylic acid [1], [2].

Its designers estimate that this glycolipid keeps more than 99% of the peptide transiently bound to albumin [4]. That binding helps protect it from breakdown and kidney filtration [4].

From 2007, Altor BioScience used the same code, ALT-801, for an unrelated cancer drug candidate (NCT00496860).

Table 1

What is pemvidutide and how is it built

PropertyPemvidutide
ClassDual glucagon receptor and GLP-1 receptor agonist; glycolipid-modified peptide [3], [4]
Length29 amino acids with an amidated C-terminus [2]
Key modificationsAib at position 2; lactam bridge between positions 16 and 20; EuPort glycolipid on the lysine at position 17 [2]
Molecular formulaC182H275N39O54 [1]
Molecular weightAbout 3,873 g/mol (PubChem computed value) [1]
IdentifiersALT-801, SP-1373, MD-1373; CAS 2538014-94-5; FDA UNII A35F525WBG [2]
Receptor potency in cell assays39 pM at the GLP-1 receptor and 42 pM at the glucagon receptor [4]
Half-life in animals52 hours in minipigs, with a mean residence time of 86 hours [3]
DeveloperAltimmune; originally Spitfire Pharma [4]
FDA approvalNone; openFDA returned no Drugs@FDA record on November 18, 2026

How does pemvidutide work?

Pemvidutide activates two receptors in the glucagon receptor family. The GLP-1 receptor supports glucose-dependent insulin release and signals fullness (see what GLP-1 is). The glucagon receptor acts mainly in the liver (see the glucagon complete guide). Nestor and colleagues note that rodent and primate livers carry glucagon receptors but not GLP-1 receptors [4].

Glucagon can raise blood sugar. The designers argue that GLP-1's glucose-dependent insulin effect can offset that risk within one molecule [4]. Trial authors add that glucagon receptor agonists act directly on the liver, raising fat burning and reducing fat production [5].

Cell findings. In cell assays, pemvidutide's potency was closely matched at the two receptors [4]. The authors contrasted this with cotadutide and survodutide, which they estimated were biased about 5:1 and 7.5:1 toward the GLP-1 receptor [4].

Animal findings. The study used mice with diet-induced obesity and biopsy-confirmed fatty liver disease. Twelve weeks of pemvidutide cut body weight by about 25% versus vehicle [4]. That was roughly twice the loss seen with an equal molar amount of semaglutide [4]. Fibrosis improved by at least one stage in 64% and 55% of two pemvidutide groups [4]. The figures were 75% on elafibranor, 42% on semaglutide and none on vehicle [4]. Spitfire Pharma funded the study, and several authors held financial interests in Altimmune [4].

What is pemvidutide being studied for?

ClinicalTrials.gov listed 10 Altimmune studies of pemvidutide or ALT-801 on November 18, 2026. Altimmune's November 2026 update names three targets: MASH, alcohol use disorder and alcohol-associated liver disease [10].

MASH. MASH is metabolic dysfunction-associated steatohepatitis, a fatty liver disease with inflammation. The phase 3 PERFORMA trial (NCT07795164) began in July 2026 and plans about 1,800 adults with F2 or F3 fibrosis [9]. Primary endpoints are MASH resolution and fibrosis improvement at 52 weeks, plus clinical outcome events over about 60 months [9].

Alcohol use disorder. The phase 2 RECLAIM trial (NCT06987513) enrolled 100 adults with alcohol use disorder and obesity or overweight. Its primary endpoint was the change in heavy drinking days per week at weeks 21 to 24. Altimmune reported positive topline results and presented them at the 2026 AASLD liver meeting [10]. An FDA end-of-phase 2 meeting is set for December 2026 [10]. We found no peer-reviewed publication of these results in PubMed.

Alcohol-associated liver disease. The phase 2 RESTORE trial (NCT07009860) enrolled 121 adults. Its primary endpoint is the change in liver stiffness measured by elastography at weeks 24 and 48. Altimmune expects topline data in the second half of 2027 [10].

Obesity. The 48-week phase 2 MOMENTUM trial (NCT05295875) enrolled 391 adults with obesity or overweight and ended in September 2023. We found no peer-reviewed report of its results in PubMed. Vitrapep's guide on how to find a peptide clinical trial explains how to read these records.

What did the key pemvidutide trials show?

12-week MASLD trial (NCT05006885). MASLD is metabolic dysfunction-associated steatotic liver disease, the broader fatty liver category that includes MASH. The trial treated 94 adults with a BMI of 28 or more and liver fat of at least 10% [5]. Median BMI was 36.2, and 29% had type 2 diabetes [5]. In the best-performing group, 55.6% reached normal liver fat of 5% or less [5].

24-week extension (NCT05292911). Of 83 people who completed the first trial, 64 stayed on their assigned treatment for 12 more weeks at 13 US sites [6]. Changes in fasting glucose and HbA1c did not differ significantly from placebo [6]. The authors reported no significant change in heart rate [6].

IMPACT (NCT05989711). This phase 2b trial randomized 212 adults with biopsy-confirmed MASH and F2 or F3 fibrosis [7]. It ran at 83 sites in the United States and Australia [7]. Mean BMI was 38.7, and 42% had type 2 diabetes [8]. Both primary endpoints were judged on liver biopsy at 24 weeks [7]. Pemvidutide met the MASH resolution endpoint but not the fibrosis improvement endpoint [7].

No biopsies were taken at 48 weeks, so only secondary endpoints were measured then [8]. Liver fat, ALT and the ELF blood score all improved more than on placebo [8]. So did cT1, an MRI measure linked to liver inflammation and fibrosis [8].

Table 2

What did the key pemvidutide trials show

TrialPopulation and sizeDesign and lengthPrimary result
MASLD trial, 2025 [5]94 treated adults with BMI 28 or more and liver fat of 10% or moreDouble-blind, placebo-controlled, three dose levels; 12 weeksLiver fat fell 46.6% to 68.5% (relative) vs 4.4% on placebo
MASLD extension, 2025 [6]64 adults who completed the 12-week trialDouble-blind, same assigned treatment; 24 weeks in totalLiver fat fell 56.3% to 76.4% vs 14.0%; weight fell 5.1% to 6.2% vs 1.4%
IMPACT, 24 weeks, 2025 [7]212 adults with biopsy-confirmed MASH and F2 or F3 fibrosisDouble-blind, placebo-controlled, two dose levels; 24 weeksMASH resolution 58% and 52% vs 20%; fibrosis improvement 33% and 36% vs 28%, not significant
IMPACT, 48 weeks, 2026 [8]The same 212 adultsSecondary endpoints only; no biopsy at 48 weeksLiver fat fell 45.2% and 54.7% vs 8.2% on placebo

Altimmune sponsored all four trials, and company employees were among the authors [5], [6], [7], [8]. Vitrapep's guide on how to evaluate peptide research explains why sponsorship and trial size matter.

What side effects have pemvidutide trials reported?

Pemvidutide has no FDA label, boxed warning or label section 6. All safety data below come from trial publications sponsored by Altimmune.

Gastrointestinal events. In IMPACT, 78% and 81% of the two pemvidutide groups reported any adverse event by week 24, versus 67% on placebo [7]. Most were mild or moderate [7]. The 48-week report lists the most frequent pemvidutide-related events, shown below [8].

Table 3

What side effects have pemvidutide trials reported

Event in IMPACT at 48 weeks [8]Pemvidutide, lower dose (N=41)Pemvidutide, higher dose (N=85)Placebo (N=86)
Nausea22%41%17%
Diarrhea12%22%8%
Constipation12%18%12%
Stopped treatment for adverse events0%1%3%

Serious events. In the 48-week IMPACT report, no severe or serious adverse event was judged related to the study drug [8]. The 12-week MASLD trial reported no severe or serious adverse events [5]. The extension had no serious events, and its two severe events on pemvidutide were judged unrelated [6].

Stopping treatment. In the extension, 3 of 45 participants on pemvidutide stopped treatment because of adverse events [6]. Nausea occurred in 33.3% of them during the extension [6].

Limits of the data. These trials were small and lasted no longer than 48 weeks, so they cannot estimate rare or long-term risks.

What is the regulatory status of pemvidutide?

Approval. Pemvidutide has no FDA approval, and Altimmune describes it as investigational [10]. We found no approval by any regulator in the sources we checked.

Development designations. Altimmune reports that FDA granted Fast Track designations for MASH and for alcohol use disorder [10]. The company says FDA also granted a second MASH designation based on 24-week IMPACT data [10]. FDA reserves that designation for serious conditions where preliminary clinical evidence suggests substantial improvement over available therapy [11]. Designations can speed development and review, but they are not approvals.

Research-labeled products. FDA says it has warned companies that illegally sold semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled "for research purposes" [12]. Those products were sold directly to consumers for human use, according to FDA [12]. The page does not name pemvidutide. A research-use-only label does not make any product legal or safe for people. See research peptides and human-use risks and why research peptides have no dose.

Compounding. FDA's page says retatrutide and cagrilintide cannot be used in compounding, but it does not address pemvidutide [12].

Sport. The WADA Prohibited List does not name pemvidutide. Its S0 class bans at all times any pharmacological substance not covered elsewhere and lacking current approval for human therapeutic use [13]. That includes drugs in clinical development [13]. See Vitrapep's WADA 2026 peptide reference.

What is still unknown about pemvidutide?

No phase 3 results exist yet. PERFORMA's 52-week biopsy readout is expected in 2029, and its outcome follow-up runs years longer [9], [10]. IMPACT did not show a significant fibrosis benefit on biopsy at 24 weeks [7]. Its 48-week findings rest on noninvasive tests, not biopsies [8].

The published human trials were sponsored by Altimmune, and none compared pemvidutide with an approved medicine [5], [6], [7]. Obesity and alcohol use disorder results have not appeared in a peer-reviewed journal that we found. Long-term safety and effects on glucose control in diabetes need larger, longer trials.

Frequently asked questions

Is pemvidutide a peptide?

Yes. It is a 29-amino-acid peptide with a glycolipid group attached. PubChem lists a computed molecular weight of about 3,873 g/mol.

Is pemvidutide FDA-approved?

No. It has no FDA approval for any use. Its Fast Track and other FDA designations are not approvals.

Who developed pemvidutide?

It began at Spitfire Pharma as SP-1373. Altimmune now develops it and funds its clinical trials.

What does ALT-801 mean?

ALT-801 is pemvidutide's development code. An older cancer program used the same code for an unrelated interleukin-2 fusion protein.

How is pemvidutide different from survodutide?

Both activate the glucagon and GLP-1 receptors. Pemvidutide's developers describe its potency at the two receptors as balanced, while they estimate survodutide favors the GLP-1 receptor. Neither is FDA-approved.

What side effects were most common in pemvidutide trials?

Nausea, diarrhea and constipation were the most frequent drug-related events in IMPACT. Few participants stopped treatment because of adverse events.

What to know now

  • Pemvidutide is a 29-amino-acid glucagon and GLP-1 dual agonist carrying a glycolipid that binds albumin.
  • In IMPACT, MASH resolution was more frequent than on placebo at 24 weeks, but fibrosis improvement was not significant.
  • Gastrointestinal events were the most frequent drug-related side effects in the published trials.
  • Pemvidutide is not FDA-approved; the phase 3 PERFORMA trial began in July 2026.

What we’re watching

  • The 52-week biopsy results from PERFORMA, which Altimmune expects in 2029.
  • Peer-reviewed publication of RECLAIM and the outcome of Altimmune's December 2026 FDA meeting on alcohol use disorder.
  • Topline RESTORE results in alcohol-associated liver disease, expected in the second half of 2027.

More for endocrine & metabolism

All 49 compounds for endocrine & metabolism

Sources: National Center for Biotechnology Information 2026; U.S. Food and Drug Administration 2026; Nestor 2021, Peptide Science, 113; Nestor 2022, Scientific Reports, 12; Harrison 2025, Journal of Hepatology, 82; Browne 2025, JHEP Reports, 7; Noureddin 2025, Lancet, 406; Noureddin 2026, Lancet Gastroenterology & Hepatology; ClinicalTrials.gov 2026; Altimmune 2026; U.S. Food and Drug Administration 2018; U.S. Food and Drug Administration 2026; World Anti-Doping Agency 2026. All 13 citations

Back to the research library

References

  1. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 171370716, the deposited structure linked to PubChem's pemvidutide substance records. https://pubchem.ncbi.nlm.nih.gov/compound/171370716
  2. U.S. Food and Drug Administration. (2026). Global Substance Registration System: Pemvidutide, UNII A35F525WBG. https://precision.fda.gov/ginas/app/ui/substances/d0e39d47-4977-4f6c-b773-55d1ff6f4a4e
  3. Nestor, J. J., Zhang, X., Jaw-Tsai, S., Parkes, D. G., & Becker, C. K. (2021). Design and characterization of a surfactant-conjugated, long-acting, balanced GLP-1/glucagon receptor dual agonist. Peptide Science, 113(5), e24221. https://doi.org/10.1002/pep2.24221
  4. Nestor, J. J., Parkes, D., Feigh, M., Suschak, J. J., & Harris, M. S. (2022). Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis. Scientific Reports, 12(1), 6666. https://pubmed.ncbi.nlm.nih.gov/35461369/
  5. Harrison, S. A., Browne, S. K., Suschak, J. J., et al. (2025). Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. Journal of Hepatology, 82(1), 7-17. https://pubmed.ncbi.nlm.nih.gov/39002641/
  6. Browne, S. K., Suschak, J. J., Tomah, S., et al. (2025). Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. JHEP Reports, 7(11), 101483. https://pubmed.ncbi.nlm.nih.gov/41113119/
  7. Noureddin, M., Harrison, S. A., Loomba, R., et al. (2025). Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet, 406(10520), 2644-2655. https://pubmed.ncbi.nlm.nih.gov/41237796/
  8. Noureddin, M., Alkhouri, N., Loomba, R., et al. (2026). Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet Gastroenterology & Hepatology. Published online November 11, 2026. https://pubmed.ncbi.nlm.nih.gov/43014327/
  9. ClinicalTrials.gov. (2026). Phase 3 study of the efficacy, safety, and clinical outcomes of pemvidutide in MASH (PERFORMA), NCT07795164. https://clinicaltrials.gov/study/NCT07795164
  10. Altimmune. (2026, November 12). Altimmune announces third quarter 2026 financial results and business update [Press release, SEC Form 8-K Exhibit 99.1]. https://www.sec.gov/Archives/edgar/data/1326190/000132619026000067/alt-ex99d1.htm
  11. U.S. Food and Drug Administration. (2018). Breakthrough therapy. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy
  12. U.S. Food and Drug Administration. (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  13. World Anti-Doping Agency. (2026). The Prohibited List. https://www.wada-ama.org/en/prohibited-list